Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Abbott Diagnostics Unit Teams Up With Big Pharma On Companion Test

This article was originally published in The Gray Sheet

Executive Summary

Abbott's molecular diagnostics business announced March 7 a collaboration with Genentech, Roche and OSI Pharmaceuticals to develop a gene test that helps select patients more likely to respond to the lung cancer drug Tarceva

You may also be interested in...



Siemens, Other Top Dx Firms Wax Molecular At AACC Lab Conference

Siemens bought its way to the top of the in vitro diagnostics market during the past two years and is now aiming to make gains in one of the fastest growing segments of that sector - molecular diagnostics

Siemens, Other Top Dx Firms Wax Molecular At AACC Lab Conference

Siemens bought its way to the top of the in vitro diagnostics market during the past two years and is now aiming to make gains in one of the fastest growing segments of that sector - molecular diagnostics

Study Shows Circulating Tumor Cell Chips Track Cancer Drug Response

Circulating tumor cell chips show promise as monitors of cancer therapy response in a study led by the Massachusetts General Hospital Cancer Center published July 2 in the New England Journal of Medicine

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT025849

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel